{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:26:01Z","timestamp":1779189961314,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013710","name":"Innovative Medicines Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["439993"],"award-info":[{"award-number":["439993"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cjco.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:37:13Z","timestamp":1617737833000},"page":"965-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis\/Meta-regression Adjusted for Confounding Factors"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-2337","authenticated-orcid":false,"given":"Terry","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Cau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew Pellan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Lamontagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith R.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksa G.","family":"Rewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent W.","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Mcculoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Luther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2021.03.001_bib0001","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cjco.2021.03.001_bib0002","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cjco.2021.03.001_bib0003","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2021.03.001_bib0004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.cjco.2021.03.001_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2021.03.001_bib0006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet."},{"key":"10.1016\/j.cjco.2021.03.001_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2021.03.001_bib0008","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0009","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1038\/ncomms4595","article-title":"Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients","volume":"5","author":"Huang","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjco.2021.03.001_bib0010","first-page":"ciaa1592","article-title":"The effect of prior ACEI\/ARB treatment on COVID-19 susceptibility and outcome: a systematic review and meta-analysis","author":"Xu","year":"2020","journal-title":"Clin infect Dis"},{"key":"10.1016\/j.cjco.2021.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","article-title":"Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis","volume":"106","author":"Flacco","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.cjco.2021.03.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"Grover","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2021.03.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105053","article-title":"Mortality in COVID-19 patients treated with ACEIs\/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction","volume":"160","author":"Alamer","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0015","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis","volume":"31","author":"Caldeira","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.cjco.2021.03.001_bib0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11906-020-01101-w","article-title":"Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities","volume":"22","author":"Patoulias","year":"2020","journal-title":"Curr Hyperten Rep"},{"key":"10.1016\/j.cjco.2021.03.001_bib0017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","article-title":"Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis","volume":"81","author":"Pirola","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.cjco.2021.03.001_bib0018","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis","author":"Liu","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40256-020-00439-5","article-title":"Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis","volume":"20","author":"Hasan","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjco.2021.03.001_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcrc.2020.07.003","article-title":"The characteristics and outcomes of 681 severe cases with COVID-19 in China","volume":"60","author":"Chen","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.cjco.2021.03.001_bib0021","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2021.03.001_bib0022","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume":"77","author":"Ren","year":"2021","journal-title":"J Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0023","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jmv.26625","article-title":"The use of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","volume":"93","author":"Wang","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0024","first-page":"pvaa138","article-title":"Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis","author":"Lee","year":"2020","journal-title":"Eur Heart JCardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2021.03.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001353","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis","volume":"7","author":"Ssentongo","year":"2020","journal-title":"Open Heart"},{"key":"10.1016\/j.cjco.2021.03.001_bib0026","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/HYPERTENSIONAHA.120.15989","article-title":"Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis","volume":"76","author":"Chan","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2021.03.001_bib0027","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.dsx.2020.06.047","article-title":"The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"14","author":"Pranata","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.cjco.2021.03.001_bib0028","first-page":"6","article-title":"Meta-regression: adjusting covariates during meta-analysis","volume":"3","author":"Ravishankar","year":"2015","journal-title":"Int J Adv Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0030","unstructured":"Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed December 1, 2020."},{"key":"10.1016\/j.cjco.2021.03.001_bib0031","series-title":"Regression Modeling Strategies","author":"Harrell","year":"2015"},{"key":"10.1016\/j.cjco.2021.03.001_bib0032","doi-asserted-by":"crossref","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert, DD. Doing meta-analysis in R: a hands-on guide. Available at: https:\/\/bookdown.org\/MathiasHarrer\/Doing_Meta_Analysis_in_R\/. Accessed October 12, 2020.","DOI":"10.1201\/9781003107347"},{"key":"10.1016\/j.cjco.2021.03.001_bib0033","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","article-title":"Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome","volume":"222","author":"Lam","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cjco.2021.03.001_bib0034","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","article-title":"Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality","volume":"6","author":"Cannata","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2021.03.001_bib0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.34067\/KID.0003792020","article-title":"Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection","volume":"1","author":"Chaudhri","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.cjco.2021.03.001_bib0036","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","article-title":"COVID-19 is more severe in patients with hypertension; ACEI\/ARB treatment does not influence clinical severity and outcome","volume":"81","author":"Hu","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.cjco.2021.03.001_bib0037","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.dsx.2020.03.016","article-title":"Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.cjco.2021.03.001_bib0038","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2021.03.001_bib0039","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2021.03.001_bib0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2021.03.001_bib0041","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/joim.13119","article-title":"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States","volume":"288","author":"Imam","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0042","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/HYPERTENSIONAHA.120.15324","article-title":"Age and multimorbidity predict death among COVID-19 patients","volume":"76","author":"Iaccarino","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2021.03.001_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.3596","article-title":"Factors associated with death in critically ill patients with coronavirus disease 2019 in the US","volume":"180","author":"Gupta","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0044","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0045","first-page":"596","article-title":"Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0046","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3122\/jabfm.2020.01.190134","article-title":"Anti-hypertensive medication combinations in the United States","volume":"33","author":"Johansen","year":"2020","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0047","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0048","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pmedr.2016.01.005","article-title":"Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: analysis from the National Ambulatory Medical Care Survey","volume":"3","author":"Ibrahim","year":"2016","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.cjco.2021.03.001_bib0049","first-page":"1342","article-title":"2017 comprehensive update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/2054358118804838","article-title":"Kidney function, ACE-inhibitor\/angiotensin receptor blocker use, and survival following hospitalization for heart failure: a cohort study","volume":"5","author":"Chiu","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.cjco.2021.03.001_bib0051","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15171\/jcvtr.2019.15","article-title":"Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study","volume":"11","author":"Ghimire","year":"2019","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0052","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/phar.2091","article-title":"Guideline-directed medical therapy and survival following hospitalization in patients with heart failure","volume":"38","author":"Tran","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjco.2021.03.001_bib0053","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.cjco.2021.03.001_bib0054","unstructured":"European Society of Cardiology. Hot line: Can ACEis and ARBs be safely continued in patients hospitalised with COVID-19? Results from the BRACE CORONA trial. Available at:https:\/\/www.escardio.org\/Congresses-&-Events\/ESC-Congress\/Congress-resources\/Congress-news\/hot-line-can-aceis-and-arbs-be-safely-continued-in-patients-hospitalised-with-covid-19-results-from-the-brace-corona-trial. Accessed December 16, 2020."},{"key":"10.1016\/j.cjco.2021.03.001_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.cjco.2021.03.001_bib0056","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1038\/srep07027","article-title":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2021.03.001_bib0057","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2021.03.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens","volume":"15","author":"Bravi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cjco.2021.03.001_bib0059","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0061","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.cjco.2021.03.001_bib0062","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/cid\/ciaa677","article-title":"Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the Northeast of France","volume":"71","author":"Oussalah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjco.2021.03.001_bib0063","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016948","article-title":"Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy","volume":"9","author":"Sardu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2021.03.001_bib0064","first-page":"21","article-title":"Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19","volume":"24","author":"\u015eenkal","year":"2020","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin-converting enzyme inhibitors and angiotensin ii receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cjco.2021.03.001_bib0066","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes In COVID-19 patients with hypertension: a single center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2021.03.001_bib0067","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106805","article-title":"COVID-19 RISk and Treatments (CORIST) Collaboration. RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies","volume":"135","author":"Di Castelnuovo","year":"2020","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0069","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/imj.15078","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalized with COVID-19","volume":"50","author":"Covino","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.cjco.2021.03.001_bib0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives","volume":"33","author":"Felice","year":"2020","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjco.2021.03.001_bib0071","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ehjcvp\/pvaa083","article-title":"Inhibitors of the renin\u2013angiotensin\u2013aldosterone system and COVID-19 in critically ill elderly patients","volume":"7","author":"Jung","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2021.03.001_bib0072","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study","volume":"71","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjco.2021.03.001_bib0073","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.recesp.2020.05.030","article-title":"Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry","volume":"74","author":"L\u00f3pez-Otero","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.cjco.2021.03.001_bib0074","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","article-title":"Renin\u2013angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study","volume":"43","author":"Matsuzawa","year":"2020","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjco.2021.03.001_bib0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40292-020-00409-7","article-title":"Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19","volume":"27","author":"Negreira-Caama\u00f1o","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.cjco.2021.03.001_bib0076","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","article-title":"Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in covid-19 pneumonia patients?","volume":"42","author":"Sel\u00e7uk","year":"2020","journal-title":"Clin Exper Hypertens"},{"key":"10.1016\/j.cjco.2021.03.001_bib0077","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1097\/HJH.0000000000002584","article-title":"Baseline use of angiotensin-converting enzyme inhibitor\/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients","volume":"38","author":"Shah","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2021.03.001_bib0078","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11684-020-0800-y","article-title":"Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis","volume":"14","author":"Xu","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.cjco.2021.03.001_bib0079","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jinf.2020.08.014","article-title":"In-hospital use of ACEI\/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension","volume":"81","author":"Yuan","year":"2020","journal-title":"J Infect"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:13:50Z","timestamp":1762632830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X21000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2589790X21000718"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2021.03.001","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis\/Meta-regression Adjusted for Confounding Factors","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}